![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: XPNPEP2 |
Gene summary for XPNPEP2 |
![]() |
Gene information | Species | Human | Gene symbol | XPNPEP2 | Gene ID | 7512 |
Gene name | X-prolyl aminopeptidase 2 | |
Gene Alias | AEACEI | |
Cytomap | Xq26.1 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | O43895 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7512 | XPNPEP2 | HCC1_Meng | Human | Liver | HCC | 1.81e-21 | 4.94e-02 | 0.0246 |
7512 | XPNPEP2 | HCC1 | Human | Liver | HCC | 1.16e-43 | 4.36e+00 | 0.5336 |
7512 | XPNPEP2 | HCC2 | Human | Liver | HCC | 9.63e-39 | 3.85e+00 | 0.5341 |
7512 | XPNPEP2 | S014 | Human | Liver | HCC | 9.71e-19 | 6.41e-01 | 0.2254 |
7512 | XPNPEP2 | S015 | Human | Liver | HCC | 1.68e-19 | 9.95e-01 | 0.2375 |
7512 | XPNPEP2 | S016 | Human | Liver | HCC | 1.58e-33 | 1.08e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
XPNPEP2 | SNV | Missense_Mutation | novel | c.783N>A | p.Phe261Leu | p.F261L | O43895 | protein_coding | tolerated(0.14) | possibly_damaging(0.472) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
XPNPEP2 | SNV | Missense_Mutation | c.925C>A | p.Arg309Ser | p.R309S | O43895 | protein_coding | tolerated(0.34) | benign(0.023) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
XPNPEP2 | SNV | Missense_Mutation | novel | c.1747N>T | p.Gly583Trp | p.G583W | O43895 | protein_coding | deleterious(0.04) | possibly_damaging(0.535) | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPNPEP2 | SNV | Missense_Mutation | rs151254296 | c.925N>T | p.Arg309Cys | p.R309C | O43895 | protein_coding | tolerated(0.11) | possibly_damaging(0.724) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
XPNPEP2 | SNV | Missense_Mutation | novel | c.1396N>A | p.Val466Ile | p.V466I | O43895 | protein_coding | tolerated(0.09) | probably_damaging(0.999) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
XPNPEP2 | SNV | Missense_Mutation | novel | c.701C>A | p.Pro234Gln | p.P234Q | O43895 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EY-A548-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
XPNPEP2 | SNV | Missense_Mutation | novel | c.416N>A | p.Pro139His | p.P139H | O43895 | protein_coding | deleterious(0.01) | benign(0.006) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
XPNPEP2 | deletion | Frame_Shift_Del | rs762212384 | c.1354delN | p.Gln454SerfsTer30 | p.Q454Sfs*30 | O43895 | protein_coding | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
XPNPEP2 | deletion | Frame_Shift_Del | rs762212384 | c.1359delG | p.Gln454SerfsTer30 | p.Q454Sfs*30 | O43895 | protein_coding | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | ||
XPNPEP2 | SNV | Missense_Mutation | rs191887278 | c.593N>T | p.Pro198Leu | p.P198L | O43895 | protein_coding | tolerated(0.14) | benign(0.018) | TCGA-BC-A10S-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | CHEMBL2103847 | TOSEDOSTAT | |
7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252827461 | ||
7512 | XPNPEP2 | DRUGGABLE GENOME, PROTEASE, ENZYME | inhibitor | 252166832 |
Page: 1 |